Pivotal, registration study of MAT2203 for the prevention of invasive fungal infections (IFIs) in patients on immunosuppressive therapy while receiving chemotherapy for hematologic malignancies

Trial Profile

Pivotal, registration study of MAT2203 for the prevention of invasive fungal infections (IFIs) in patients on immunosuppressive therapy while receiving chemotherapy for hematologic malignancies

Planning
Phase of Trial: Phase III

Latest Information Update: 25 Jan 2017

At a glance

  • Drugs Amphotericin B (Primary)
  • Indications Aspergillosis; Candidiasis; Cryptococcal meningitis; Mycoses
  • Focus Registrational; Therapeutic Use
  • Sponsors Matinas BioPharma
  • Most Recent Events

    • 25 Jan 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top